Welcome

Amgen Seeks High Court Eye on Sanofi’s Defeat of Antibody Patent

Nov. 23, 2021, 9:26 PM

Amgen Inc. asked the U.S. Supreme Court to step into a long-running dispute with Sanofi and Regeneron Pharmaceuticals Inc. over the fate of its cholesterol drug patents.

The U.S. Court of Appeals for the Federal Circuit held in February that patents on Amgen’s Repatha that covered hundreds of distinct antibodies were too broad to be valid, as they wouldn’t allow a skilled artisan to recreate all possible variations of the invention without undue experimentation.

Amgen told the high court in its petition for review that the Federal Circuit’s ruling “defies more than a century” of Supreme Court precedent and its ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.